Trial Outcomes & Findings for Moxy Drug Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Femoropopliteal Arteries (NCT NCT01412541)

NCT ID: NCT01412541

Last Updated: 2020-05-12

Results Overview

Composite of freedom from all-cause peri-operative (≤30 day) death and freedom at 1 year from the following: index limb amputation (above or below the ankle), index limb re-intervention, and index-limb-related death.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

532 participants

Primary outcome timeframe

12 months post index procedure

Results posted on

2020-05-12

Participant Flow

Participant milestones

Participant milestones
Measure
Lutonix 035 Drug Coated Balloon PTA Catheter (Lutonix DCB)
Test group: Formerly called the Moxy Drug Coated Balloon, the Lutonix DCB is a paclitaxel coated balloon catheter Subjects were randomized 2:1 to the Lutonix DCB or standard angioplasty balloon.
Standard Uncoated Angioplasty Balloon
Control group: standard uncoated PTA catheter Subjects were randomized 2:1 to the Lutonix DCB or standard angioplasty balloon.
Overall Study
STARTED
372
160
Overall Study
COMPLETED
246
117
Overall Study
NOT COMPLETED
126
43

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Moxy Drug Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Femoropopliteal Arteries

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Lutonix 035 Drug Coated Balloon PTA Catheter (Lutonix DCB)
n=372 Participants
Test group: Formerly called the Moxy Drug Coated Balloon, the Lutonix DCB is a paclitaxel coated balloon catheter Subjects were randomized 2:1 to the Lutonix DCB or standard angioplasty balloon.
Standard Uncoated Angioplasty Balloon
n=160 Participants
Control group: standard uncoated PTA catheter Subjects were randomized 2:1 to the Lutonix DCB or standard angioplasty balloon.
Total
n=532 Participants
Total of all reporting groups
Age, Continuous
68 years
STANDARD_DEVIATION 10.0 • n=39 Participants
69.0 years
STANDARD_DEVIATION 9.0 • n=41 Participants
68.2 years
STANDARD_DEVIATION 9.7 • n=35 Participants
Sex: Female, Male
Female
145 Participants
n=39 Participants
53 Participants
n=41 Participants
198 Participants
n=35 Participants
Sex: Female, Male
Male
227 Participants
n=39 Participants
107 Participants
n=41 Participants
334 Participants
n=35 Participants

PRIMARY outcome

Timeframe: 12 months post index procedure

Population: The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.

Composite of freedom from all-cause peri-operative (≤30 day) death and freedom at 1 year from the following: index limb amputation (above or below the ankle), index limb re-intervention, and index-limb-related death.

Outcome measures

Outcome measures
Measure
Standard Uncoated Angioplasty Balloon
n=146 Participants
Control group: standard uncoated PTA catheter Subjects were randomized 2:1 to the Lutonix DCB or standard angioplasty balloon.
Moxy Drug Coated Balloon
n=335 Participants
Paclitaxel coated balloon catheter Moxy Drug Coated Balloon: Subjects will be randomized 2:1 to the drug coated or standard angioplasty balloon
Percentage of Participants With Composite Freedom From All-Cause Peri-Operative (≤30 Day) Death and Freedom From Index Limb Amputation, Index Limb Re-Intervention, and Index-Limb-Related Death at 12 Months Post Index Procedure
79.5 Percentage of participants
Interval 72.9 to 86.0
85.4 Percentage of participants
Interval 81.6 to 89.2

PRIMARY outcome

Timeframe: 12 months post index procedure

Population: The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.

Primary Patency is defined as the absence of target lesion restenosis (defined by DUS peak systolic velocity ratio (PSVR) ≥2.5) and freedom from target lesion revascularization (TLR).

Outcome measures

Outcome measures
Measure
Standard Uncoated Angioplasty Balloon
n=137 Participants
Control group: standard uncoated PTA catheter Subjects were randomized 2:1 to the Lutonix DCB or standard angioplasty balloon.
Moxy Drug Coated Balloon
n=314 Participants
Paclitaxel coated balloon catheter Moxy Drug Coated Balloon: Subjects will be randomized 2:1 to the drug coated or standard angioplasty balloon
Percentage of Participants With Primary Patency of the Target Lesion at 12 Months Post Index Procedure
54.0 Percentage of participants
Interval 45.7 to 62.4
66.6 Percentage of participants
Interval 61.3 to 71.8

SECONDARY outcome

Timeframe: At time of Index Procedure

Population: The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.

Device Success was defined as the achievement of successful delivery and deployment of the study device(s) as intended at the intended target lesion, without balloon rupture or inflation/deflation abnormalities and a successful withdrawal of the study system.

Outcome measures

Outcome measures
Measure
Standard Uncoated Angioplasty Balloon
n=180 Devices
Control group: standard uncoated PTA catheter Subjects were randomized 2:1 to the Lutonix DCB or standard angioplasty balloon.
Moxy Drug Coated Balloon
n=432 Devices
Paclitaxel coated balloon catheter Moxy Drug Coated Balloon: Subjects will be randomized 2:1 to the drug coated or standard angioplasty balloon
Number of Acute Device Success at Time of Index Procedure
180 Devices
430 Devices

SECONDARY outcome

Timeframe: At time of Index Procedure

Population: The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.

Technical Success is defined as successful access and deployment of the device and visual estimate of ≤30% diameter residual stenosis during the index procedure without deployment of a bailout stent. Procedural Success is defined as attainment of ≤30% residual stenosis in the treatment area by independent core lab analysis without serious adverse events during the index procedure.

Outcome measures

Outcome measures
Measure
Standard Uncoated Angioplasty Balloon
n=160 Participants
Control group: standard uncoated PTA catheter Subjects were randomized 2:1 to the Lutonix DCB or standard angioplasty balloon.
Moxy Drug Coated Balloon
n=372 Participants
Paclitaxel coated balloon catheter Moxy Drug Coated Balloon: Subjects will be randomized 2:1 to the drug coated or standard angioplasty balloon
Number of Participants With Technical and Procedural Success
Technical Success
138 Participants
282 Participants
Number of Participants With Technical and Procedural Success
Procedural Success
138 Participants
281 Participants

SECONDARY outcome

Timeframe: 6, 12, and 24 months post index procedure

Population: The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.

Primary Patency is defined as the absence of target lesion restenosis (defined by core lab adjudication or strict application of PSVR thresholds) and freedom from target lesion revascularization (TLR).

Outcome measures

Outcome measures
Measure
Standard Uncoated Angioplasty Balloon
n=160 Participants
Control group: standard uncoated PTA catheter Subjects were randomized 2:1 to the Lutonix DCB or standard angioplasty balloon.
Moxy Drug Coated Balloon
n=372 Participants
Paclitaxel coated balloon catheter Moxy Drug Coated Balloon: Subjects will be randomized 2:1 to the drug coated or standard angioplasty balloon
Number of Participants With Primary Patency at 6, 12, and 24 Months Post Index Procedure
12 months post index procedure
74 Participants
209 Participants
Number of Participants With Primary Patency at 6, 12, and 24 Months Post Index Procedure
6 months post index procedure
92 Participants
263 Participants
Number of Participants With Primary Patency at 6, 12, and 24 Months Post Index Procedure
24 months post index procedure
60 Participants
160 Participants

SECONDARY outcome

Timeframe: 6, 12, and 24 months post index procedure

Population: The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.

Percentage of subjects with Alternative Primary Patency based on alternative definitions of duplex ultrasound (DUS) peak systolic velocity ratio (PSVR) \<2.0 and \<3.0 at 6, 12, and 24 months post index procedure. DUS PSVR was calculated by dividing the maximum peak systolic velocity (PSV) from the stenosis by the PSV from the nearest segment of normal artery above the site of increase.

Outcome measures

Outcome measures
Measure
Standard Uncoated Angioplasty Balloon
n=160 Participants
Control group: standard uncoated PTA catheter Subjects were randomized 2:1 to the Lutonix DCB or standard angioplasty balloon.
Moxy Drug Coated Balloon
n=372 Participants
Paclitaxel coated balloon catheter Moxy Drug Coated Balloon: Subjects will be randomized 2:1 to the drug coated or standard angioplasty balloon
Number of Participants With Alternative Primary Patency at 6, 12, and 24 Months Post Index Procedure
DUS PSVR <3.0 : 6 months post index procedure
98 Participants
259 Participants
Number of Participants With Alternative Primary Patency at 6, 12, and 24 Months Post Index Procedure
DUS PSVR <3.0 : 12 months post index procedure
73 Participants
197 Participants
Number of Participants With Alternative Primary Patency at 6, 12, and 24 Months Post Index Procedure
DUS PSVR <2.0 : 24 months post index procdure
38 Participants
106 Participants
Number of Participants With Alternative Primary Patency at 6, 12, and 24 Months Post Index Procedure
DUS PSVR <3.0 : 24 months post index procdure
48 Participants
131 Participants
Number of Participants With Alternative Primary Patency at 6, 12, and 24 Months Post Index Procedure
DUS PSVR <2.0 : 6 months post index procedure
74 Participants
220 Participants
Number of Participants With Alternative Primary Patency at 6, 12, and 24 Months Post Index Procedure
DUS PSVR <2.0 : 12 months post index procedure
62 Participants
158 Participants

SECONDARY outcome

Timeframe: 6, 12, and 24 months post index porcedure

Population: The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.

DUS Clinical Patency defined as DUS PSVR \<2.5 without prior clinically driven target lesion revascularization (TLR).

Outcome measures

Outcome measures
Measure
Standard Uncoated Angioplasty Balloon
n=160 Participants
Control group: standard uncoated PTA catheter Subjects were randomized 2:1 to the Lutonix DCB or standard angioplasty balloon.
Moxy Drug Coated Balloon
n=372 Participants
Paclitaxel coated balloon catheter Moxy Drug Coated Balloon: Subjects will be randomized 2:1 to the drug coated or standard angioplasty balloon
Number of Participants With Duplex Ultrasound (DUS) Clinical Patency at 6, 12, and 24 Months Post Index Procedure
6 months post index procedure
90 Participants
252 Participants
Number of Participants With Duplex Ultrasound (DUS) Clinical Patency at 6, 12, and 24 Months Post Index Procedure
12 months post index procedure
69 Participants
188 Participants
Number of Participants With Duplex Ultrasound (DUS) Clinical Patency at 6, 12, and 24 Months Post Index Procedure
24 months post index procedure
42 Participants
123 Participants

SECONDARY outcome

Timeframe: 6, 12, and 24 months post index procedure

Population: The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.

Outcome measures

Outcome measures
Measure
Standard Uncoated Angioplasty Balloon
n=160 Participants
Control group: standard uncoated PTA catheter Subjects were randomized 2:1 to the Lutonix DCB or standard angioplasty balloon.
Moxy Drug Coated Balloon
n=372 Participants
Paclitaxel coated balloon catheter Moxy Drug Coated Balloon: Subjects will be randomized 2:1 to the drug coated or standard angioplasty balloon
Number of Participants With Freedom From Target Lesion Revascularization (TLR) Clinically-driven at 6, 12, and 24 Months Post Index Procedure
12 months post index procedure
122 Participants
296 Participants
Number of Participants With Freedom From Target Lesion Revascularization (TLR) Clinically-driven at 6, 12, and 24 Months Post Index Procedure
24 months post index procedure
104 Participants
250 Participants
Number of Participants With Freedom From Target Lesion Revascularization (TLR) Clinically-driven at 6, 12, and 24 Months Post Index Procedure
6 months post index procedure
144 Participants
329 Participants

SECONDARY outcome

Timeframe: 6, 12, and 24 months post index procedure

Population: The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.

The endpoint summarizes the change in index-limb Rutherford Classification of participants from baseline through 24 months. Data is presented as shift from baseline Rutherford Classification data using the following categories: 1) Improvement, 2) Same, and 3) Worsened.

Outcome measures

Outcome measures
Measure
Standard Uncoated Angioplasty Balloon
n=160 Participants
Control group: standard uncoated PTA catheter Subjects were randomized 2:1 to the Lutonix DCB or standard angioplasty balloon.
Moxy Drug Coated Balloon
n=372 Participants
Paclitaxel coated balloon catheter Moxy Drug Coated Balloon: Subjects will be randomized 2:1 to the drug coated or standard angioplasty balloon
Improvement in Rutherford Classification Scores at 6, 12, and 24 Months Post Index Procedure Compared to Baseline
6 months from baseline · Improved
118 Participants
290 Participants
Improvement in Rutherford Classification Scores at 6, 12, and 24 Months Post Index Procedure Compared to Baseline
6 months from baseline · Worsened
5 Participants
13 Participants
Improvement in Rutherford Classification Scores at 6, 12, and 24 Months Post Index Procedure Compared to Baseline
12 months from baseline · Same
21 Participants
27 Participants
Improvement in Rutherford Classification Scores at 6, 12, and 24 Months Post Index Procedure Compared to Baseline
12 months from baseline · Worsened
2 Participants
9 Participants
Improvement in Rutherford Classification Scores at 6, 12, and 24 Months Post Index Procedure Compared to Baseline
24 months from baseline · Same
15 Participants
31 Participants
Improvement in Rutherford Classification Scores at 6, 12, and 24 Months Post Index Procedure Compared to Baseline
6 months from baseline · Same
22 Participants
30 Participants
Improvement in Rutherford Classification Scores at 6, 12, and 24 Months Post Index Procedure Compared to Baseline
12 months from baseline · Improved
108 Participants
273 Participants
Improvement in Rutherford Classification Scores at 6, 12, and 24 Months Post Index Procedure Compared to Baseline
24 months from baseline · Improved
106 Participants
242 Participants
Improvement in Rutherford Classification Scores at 6, 12, and 24 Months Post Index Procedure Compared to Baseline
24 months from baseline · Worsened
1 Participants
7 Participants

SECONDARY outcome

Timeframe: 6, 12, and 24 months from baseline

Population: The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.

Mean change from baseline values. The Ankle Brachial Index (ABI) is defined as a ratio of ankle to brachial (upper arm) artery systolic blood pressure and aims at determining how well the blood is flowing in the legs.

Outcome measures

Outcome measures
Measure
Standard Uncoated Angioplasty Balloon
n=160 Participants
Control group: standard uncoated PTA catheter Subjects were randomized 2:1 to the Lutonix DCB or standard angioplasty balloon.
Moxy Drug Coated Balloon
n=372 Participants
Paclitaxel coated balloon catheter Moxy Drug Coated Balloon: Subjects will be randomized 2:1 to the drug coated or standard angioplasty balloon
Change in Resting Ankle Brachial Index (ABI) at 6, 12, and 24 Months Compared to Baseline
12 months post index procedure
0.18 Index
Standard Deviation 0.25
0.18 Index
Standard Deviation 0.24
Change in Resting Ankle Brachial Index (ABI) at 6, 12, and 24 Months Compared to Baseline
24 months post index procedure
0.17 Index
Standard Deviation 0.24
0.14 Index
Standard Deviation 0.27
Change in Resting Ankle Brachial Index (ABI) at 6, 12, and 24 Months Compared to Baseline
6 months post index procedure
0.16 Index
Standard Deviation 0.22
0.20 Index
Standard Deviation 0.24

SECONDARY outcome

Timeframe: 6, 12, and 24 months from baseline

Population: The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.

The data bellow is presented as a Mean change in scores for the Six Minute Walk Test scores at 6, 12, and 24 months compared to baseline.

Outcome measures

Outcome measures
Measure
Standard Uncoated Angioplasty Balloon
n=160 Participants
Control group: standard uncoated PTA catheter Subjects were randomized 2:1 to the Lutonix DCB or standard angioplasty balloon.
Moxy Drug Coated Balloon
n=372 Participants
Paclitaxel coated balloon catheter Moxy Drug Coated Balloon: Subjects will be randomized 2:1 to the drug coated or standard angioplasty balloon
Change in Six Minute Walk Test Distance at 6, 12, and 24 Months Compared to Baseline
6 months from baseline
61.1 Meters
Standard Deviation 213.4
42.5 Meters
Standard Deviation 205.7
Change in Six Minute Walk Test Distance at 6, 12, and 24 Months Compared to Baseline
24 months from baseline
47.1 Meters
Standard Deviation 209.2
48.6 Meters
Standard Deviation 190.6
Change in Six Minute Walk Test Distance at 6, 12, and 24 Months Compared to Baseline
12 months from baseline
37.4 Meters
Standard Deviation 120
45.0 Meters
Standard Deviation 227.5

SECONDARY outcome

Timeframe: 6, 12, and 24 months

Population: The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.

Mean change in EuroQol (EQ-5D) scores at 6, 12, and 24 months compared to baseline. The EurolQol-5D system rates quality of life using five dimensions including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels of ratings, that is, no problems, slight problems, moderate problems, severe problems and extreme problems that can be selected. A visual scale allows participants to report their own perception of their health status. The overall scores range from 0 (worst) to 100 (best). Please note that the data in the table below represent the mean changes in overall scores for each group compared to their baseline data.

Outcome measures

Outcome measures
Measure
Standard Uncoated Angioplasty Balloon
n=160 Participants
Control group: standard uncoated PTA catheter Subjects were randomized 2:1 to the Lutonix DCB or standard angioplasty balloon.
Moxy Drug Coated Balloon
n=372 Participants
Paclitaxel coated balloon catheter Moxy Drug Coated Balloon: Subjects will be randomized 2:1 to the drug coated or standard angioplasty balloon
Change in European Quality of Life 5 Dimensions (EuroQol -5D) Scores at 6, 12, and 24 Months Compared to Baseline.
24 months from baseline
0.09 Score on a scale
Standard Deviation 0.20
0.07 Score on a scale
Standard Deviation 0.23
Change in European Quality of Life 5 Dimensions (EuroQol -5D) Scores at 6, 12, and 24 Months Compared to Baseline.
6 months from baseline
0.10 Score on a scale
Standard Deviation 0.18
0.08 Score on a scale
Standard Deviation 0.21
Change in European Quality of Life 5 Dimensions (EuroQol -5D) Scores at 6, 12, and 24 Months Compared to Baseline.
12 months from baseline
0.08 Score on a scale
Standard Deviation 0.20
0.09 Score on a scale
Standard Deviation 0.20

SECONDARY outcome

Timeframe: 6, 12, and 24 months

Population: The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.

Mean change from Baseline on the Short Form (SF-36 v2) Quality of Life Questionnaire at 6, 12, and 24 months. The SF-36 v2 United States (US) is a brief measure of general health status. The physical health measure of the test comprises four scales, that is, physical functioning (10 items), role-physical (4 items), bodily pain (2 items), and general health (5 items). The scores range between 0 and 100 (with higher scores indicating better health). In the results presented below, a positive Mean represents an increase in the average health score while a negative Mean represents a decrease in the same mean score compared to baseline measure.

Outcome measures

Outcome measures
Measure
Standard Uncoated Angioplasty Balloon
n=160 Participants
Control group: standard uncoated PTA catheter Subjects were randomized 2:1 to the Lutonix DCB or standard angioplasty balloon.
Moxy Drug Coated Balloon
n=372 Participants
Paclitaxel coated balloon catheter Moxy Drug Coated Balloon: Subjects will be randomized 2:1 to the drug coated or standard angioplasty balloon
Change in Score on the Short Form Quality of Life Measure (Physical Component) at 6, 12, and 24 Months Compared to Baseline.
6 months from baseline
6.3 score on a scale
Standard Deviation 10.0
6.6 score on a scale
Standard Deviation 11.4
Change in Score on the Short Form Quality of Life Measure (Physical Component) at 6, 12, and 24 Months Compared to Baseline.
12 months from baseline
5.4 score on a scale
Standard Deviation 10.2
6.0 score on a scale
Standard Deviation 11.4
Change in Score on the Short Form Quality of Life Measure (Physical Component) at 6, 12, and 24 Months Compared to Baseline.
24 months from baseline
5.2 score on a scale
Standard Deviation 9.9
4.5 score on a scale
Standard Deviation 11.2

SECONDARY outcome

Timeframe: 6, 12, and 24 months from baseline

Population: The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.

Mean change in quality of life (mental component) on Short-form 36 (SF-36 v2) from baseline at 6, 12, and 24 months. The SF-36 v2 United States (US) is a brief measure of general health status. The mental health measure comprises four scales, that is, vitality (4 items), social functioning (2 items), role-emotional (3 items), and mental health (5 items). The scores range from 0 to 100 (with higher scores indicating better health). In the results presented below, a positive Mean represents an increase in the average health score while a negative Mean represents a decrease in the same mean score compared to baseline measure.

Outcome measures

Outcome measures
Measure
Standard Uncoated Angioplasty Balloon
n=160 Participants
Control group: standard uncoated PTA catheter Subjects were randomized 2:1 to the Lutonix DCB or standard angioplasty balloon.
Moxy Drug Coated Balloon
n=372 Participants
Paclitaxel coated balloon catheter Moxy Drug Coated Balloon: Subjects will be randomized 2:1 to the drug coated or standard angioplasty balloon
Change in Quality of Life (Mental Component) on the Short-form 36 (SF-36 v2) at 6, 12, and 24 Months Compared to Baseline
6 months from baseline
1.6 score on a scale
Standard Deviation 14.1
-0.7 score on a scale
Standard Deviation 12.0
Change in Quality of Life (Mental Component) on the Short-form 36 (SF-36 v2) at 6, 12, and 24 Months Compared to Baseline
12 months from baseline
0.4 score on a scale
Standard Deviation 13.4
0.2 score on a scale
Standard Deviation 12.4
Change in Quality of Life (Mental Component) on the Short-form 36 (SF-36 v2) at 6, 12, and 24 Months Compared to Baseline
24 months from baseline
1.8 score on a scale
Standard Deviation 13.5
-0.4 score on a scale
Standard Deviation 13.0

SECONDARY outcome

Timeframe: 30 days post index procedure

Population: The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.

Number of subjects with Freedom from all-cause death, index limb amputation above the ankle and Target Vessel Revascularization (TVR) (VIVA Safety Endpoint)

Outcome measures

Outcome measures
Measure
Standard Uncoated Angioplasty Balloon
n=156 Participants
Control group: standard uncoated PTA catheter Subjects were randomized 2:1 to the Lutonix DCB or standard angioplasty balloon.
Moxy Drug Coated Balloon
n=362 Participants
Paclitaxel coated balloon catheter Moxy Drug Coated Balloon: Subjects will be randomized 2:1 to the drug coated or standard angioplasty balloon
Number of Subjects With Freedom From Death, Index-Limb Amputation, and Target Vessel Revascularization (TVR) at 30 Days Post Index Porcedure
155 Participants
361 Participants

SECONDARY outcome

Timeframe: 1, 6, 24, 36, 48, and 60 months post index procedure

Population: The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.

Outcome measures

Outcome measures
Measure
Standard Uncoated Angioplasty Balloon
n=160 Participants
Control group: standard uncoated PTA catheter Subjects were randomized 2:1 to the Lutonix DCB or standard angioplasty balloon.
Moxy Drug Coated Balloon
n=372 Participants
Paclitaxel coated balloon catheter Moxy Drug Coated Balloon: Subjects will be randomized 2:1 to the drug coated or standard angioplasty balloon
Number of Participants With Composite of Freedom From All-Cause Perioperative (<30 Day) Death and Freedom From the Following at 1,6, 24, 36, 48, and 60 Months: Index Limb Amputation, Index Limb Re-intervention, and Index Limb Related Death
1 month post index procedure
155 Participants
360 Participants
Number of Participants With Composite of Freedom From All-Cause Perioperative (<30 Day) Death and Freedom From the Following at 1,6, 24, 36, 48, and 60 Months: Index Limb Amputation, Index Limb Re-intervention, and Index Limb Related Death
36 months post index procedure
87 Participants
212 Participants
Number of Participants With Composite of Freedom From All-Cause Perioperative (<30 Day) Death and Freedom From the Following at 1,6, 24, 36, 48, and 60 Months: Index Limb Amputation, Index Limb Re-intervention, and Index Limb Related Death
48 months post index procedure
74 Participants
189 Participants
Number of Participants With Composite of Freedom From All-Cause Perioperative (<30 Day) Death and Freedom From the Following at 1,6, 24, 36, 48, and 60 Months: Index Limb Amputation, Index Limb Re-intervention, and Index Limb Related Death
60 months post index procedure
69 Participants
160 Participants
Number of Participants With Composite of Freedom From All-Cause Perioperative (<30 Day) Death and Freedom From the Following at 1,6, 24, 36, 48, and 60 Months: Index Limb Amputation, Index Limb Re-intervention, and Index Limb Related Death
6 months post index procedure
140 Participants
324 Participants
Number of Participants With Composite of Freedom From All-Cause Perioperative (<30 Day) Death and Freedom From the Following at 1,6, 24, 36, 48, and 60 Months: Index Limb Amputation, Index Limb Re-intervention, and Index Limb Related Death
24 months post index procedure
94 Participants
240 Participants

SECONDARY outcome

Timeframe: 1, 6, 12, 24, 36, 48, and 60 months post index procedure

Population: The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.

Amputation defined as above the ankle free survival (AFS). PPI = Post index procedure.

Outcome measures

Outcome measures
Measure
Standard Uncoated Angioplasty Balloon
n=160 Participants
Control group: standard uncoated PTA catheter Subjects were randomized 2:1 to the Lutonix DCB or standard angioplasty balloon.
Moxy Drug Coated Balloon
n=372 Participants
Paclitaxel coated balloon catheter Moxy Drug Coated Balloon: Subjects will be randomized 2:1 to the drug coated or standard angioplasty balloon
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Death : 6 months PPI
2 participants
4 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Death : 12 months PPI
4 participants
10 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Death : 60 months PPI
17 participants
64 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Major Amputation : 1 month PPI
0 participants
0 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Amputation Free Survival : 6 months PPI
152 participants
349 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Major Vascular Complication : 24 months PPI
10 participants
32 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Death : 1 month PPI
0 participants
0 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Death : 24 months PPI
8 participants
25 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Death : 36 months PPI
10 participants
37 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Death : 48 months PPI
14 participants
54 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Major Amputation : 6 months PPI
0 participants
1 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Major Amputation : 12 months PPI
0 participants
1 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Major Amputation : 24 months PPI
0 participants
1 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Major Amputation : 36 months PPI
0 participants
1 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Major Amputation : 48 months PPI
1 participants
2 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Major Amputation : 60 months PPI
1 participants
2 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Minor Amputation : 1 month PPI
0 participants
0 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Minor Amputation : 6 months PPI
0 participants
0 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Minor Amputation : 12 months PPI
0 participants
0 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Minor Amputation : 24 months PPI
0 participants
1 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Minor Amputation : 36 months PPI
0 participants
2 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Minor Amputation : 48 months PPI
0 participants
3 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Minor Amputation : 60 months PPI
0 participants
3 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Amputation Free Survival : 1 month PPI
156 participants
362 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Amputation Free Survival : 12 months PPI
144 participants
331 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Amputation Free Survival : 24 months PPI
133 participants
301 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Amputation Free Survival : 36 months PPI
129 participants
283 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Amputation Free Survival : 48 months PPI
122 participants
261 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Amputation Free Survival : 60 months PPI
115 participants
242 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Total TLR : 1 month PPI
0 participants
1 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Total TLR : 6 months PPI
9 participants
20 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Total TLR : 12 months PPI
24 participants
38 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Total TLR : 24 months PPI
34 participants
59 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Total TLR : 36 months PPI
38 participants
69 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Total TLR : 48 months PPI
45 participants
78 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Total TLR : 60 months PPI
46 participants
85 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Total TVR : 1 month PPI
1 participants
1 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Total TVR : 6 months PPI
12 participants
22 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Total TVR : 12 months PPI
26 participants
42 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Total TVR : 24 months PPI
39 participants
63 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Total TVR : 36 months PPI
43 participants
73 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Total TVR : 48 months PPI
53 participants
83 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Total TVR : 60 months PPI
54 participants
90 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Reintervention for Thrombosis : 1 month PPI
1 participants
1 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Reintervention for Thrombosis : 6 months PPI
1 participants
1 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Reintervention for Thrombosis : 12 months PPI
1 participants
1 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Reintervention for Thrombosis : 24 months PPI
1 participants
1 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Reintervention for Thrombosis : 36 months PPI
1 participants
2 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Reintervention for Thrombosis : 48 months PPI
1 participants
2 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Reintervention for Thrombosis : 60 months PPI
1 participants
2 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Cardiovascular Hospitalization : 1 month PPI
0 participants
1 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Cardiovascular Hospitalization : 6 months PPI
3 participants
20 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Cardiovascular Hospitalization : 12 months PPI
10 participants
31 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Cardiovascular Hospitalization : 24 months PPI
21 participants
52 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Cardiovascular Hospitalization : 36 months PPI
23 participants
55 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Cardiovascular Hospitalization : 48 months PPI
23 participants
55 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Cardiovascular Hospitalization : 60 months PPI
23 participants
55 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Major Vascular Complication : 1 month PPI
2 participants
15 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Major Vascular Complication : 6 months PPI
4 participants
19 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Major Vascular Complication : 12 months PPI
7 participants
22 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Major Vascular Complication : 36 months PPI
13 participants
36 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Major Vascular Complication : 48 months PPI
13 participants
39 participants
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Major Vascular Complication : 60 months PPI
13 participants
39 participants

SECONDARY outcome

Timeframe: 6, 12, and 24 months post index procedure

Population: The number of participants (n) varies from the total number of participants (N) in the study as n depends on the number of participants for which data was available at the given time-point analysis.

The WIQ assesses 3 categories of activities that include 1) walking distance, 2) stair-climbing, and 3) walking speed. Each question requires participants to rate their degree of difficulty with the activity on a scale of 0 (unable) to 4 (no problem). Final scores range from 0% to 100%, with lower percentages indicating higher levels of difficulties with activities.The results below represent the mean differences in total Walking Impairment Questionnaire (WIQ) scores at 6, 12, and 24 months, compared to baseline assessment scores.

Outcome measures

Outcome measures
Measure
Standard Uncoated Angioplasty Balloon
n=160 Participants
Control group: standard uncoated PTA catheter Subjects were randomized 2:1 to the Lutonix DCB or standard angioplasty balloon.
Moxy Drug Coated Balloon
n=372 Participants
Paclitaxel coated balloon catheter Moxy Drug Coated Balloon: Subjects will be randomized 2:1 to the drug coated or standard angioplasty balloon
Change in Walking Impairment Questionnaire (WIQ) Scores at 6, 12, and 24 Months Post Index Procedure Compared to Baseline.
6 months from baseline
20.5 score on a scale
Standard Deviation 28.7
26.6 score on a scale
Standard Deviation 28.8
Change in Walking Impairment Questionnaire (WIQ) Scores at 6, 12, and 24 Months Post Index Procedure Compared to Baseline.
12 months from baseline
19.2 score on a scale
Standard Deviation 26.5
23.9 score on a scale
Standard Deviation 27.6
Change in Walking Impairment Questionnaire (WIQ) Scores at 6, 12, and 24 Months Post Index Procedure Compared to Baseline.
24 months from baseline
16.9 score on a scale
Standard Deviation 26.7
22.4 score on a scale
Standard Deviation 28.8

Adverse Events

Lutonix 035 Drug Coated Balloon (Lutonix DCB)

Serious events: 289 serious events
Other events: 316 other events
Deaths: 64 deaths

Standard Uncoated Angioplasty Balloon

Serious events: 125 serious events
Other events: 126 other events
Deaths: 17 deaths

Serious adverse events

Serious adverse events
Measure
Lutonix 035 Drug Coated Balloon (Lutonix DCB)
n=372 participants at risk
Test group: Formerly called the Moxy Drug Coated Balloon, the Lutonix DCB is a paclitaxel coated balloon catheter Subjects were randomized 2:1 to the Lutonix DCB or standard angioplasty balloon.
Standard Uncoated Angioplasty Balloon
n=160 participants at risk
Control group: standard uncoated PTA catheter Subjects were randomized 2:1 to the Lutonix DCB or standard angioplasty balloon.
General disorders
Carcinoma
7.0%
26/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
3.1%
5/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
General disorders
Other
17.5%
65/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
13.1%
21/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Vascular disorders
Arterial occlusion
3.2%
12/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
5.6%
9/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Cardiac disorders
Angina, stable
7.5%
28/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
5.0%
8/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Cardiac disorders
Angina, Unstable
2.7%
10/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
3.1%
5/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Cardiac disorders
Arrhytmia, Other
3.8%
14/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
6.2%
10/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Cardiac disorders
Chronic heart failure
4.8%
18/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
5.0%
8/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Cardiac disorders
Hypertension
2.7%
10/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
6.2%
10/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Cardiac disorders
Myocardial infarction
6.5%
24/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
10.6%
17/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Cardiac disorders
Cardiovascular, Other
15.9%
59/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
12.5%
20/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Gastrointestinal disorders
Diarrhea
0.54%
2/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
3.8%
6/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Gastrointestinal disorders
Gastrointestinal bleeding
5.4%
20/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
5.0%
8/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Gastrointestinal disorders
Gastrointestinal, Others
5.9%
22/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
6.9%
11/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Infections and infestations
Local infection
2.2%
8/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
5.0%
8/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Nervous system disorders
Stroke -ischemic
4.0%
15/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
1.9%
3/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Nervous system disorders
Other neurological - nervous system
4.0%
15/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
4.4%
7/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Respiratory, thoracic and mediastinal disorders
Carcinoma
3.2%
12/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
1.9%
3/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Respiratory, thoracic and mediastinal disorders
Other respiratory
5.6%
21/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
3.8%
6/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Respiratory, thoracic and mediastinal disorders
Pneumonia
8.6%
32/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
4.4%
7/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Musculoskeletal and connective tissue disorders
Fracture (bone)
3.5%
13/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
6.2%
10/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Musculoskeletal and connective tissue disorders
Claudication
0.81%
3/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
3.8%
6/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Musculoskeletal and connective tissue disorders
Other skeletal, spine and muscular system
8.6%
32/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
7.5%
12/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Vascular disorders
Restenosis
8.6%
32/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
13.8%
22/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Vascular disorders
Occlusion/closure
1.6%
6/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
3.1%
5/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Renal and urinary disorders
Renal failure/ insufficiency
5.4%
20/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
5.6%
9/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Renal and urinary disorders
Urinary infection
2.2%
8/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
3.1%
5/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Renal and urinary disorders
Other genito-urinary system
2.7%
10/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
3.1%
5/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Vascular disorders
Atherosclerosis
4.0%
15/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
6.9%
11/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Vascular disorders
Stenosis
11.3%
42/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
14.4%
23/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.

Other adverse events

Other adverse events
Measure
Lutonix 035 Drug Coated Balloon (Lutonix DCB)
n=372 participants at risk
Test group: Formerly called the Moxy Drug Coated Balloon, the Lutonix DCB is a paclitaxel coated balloon catheter Subjects were randomized 2:1 to the Lutonix DCB or standard angioplasty balloon.
Standard Uncoated Angioplasty Balloon
n=160 participants at risk
Control group: standard uncoated PTA catheter Subjects were randomized 2:1 to the Lutonix DCB or standard angioplasty balloon.
General disorders
Hematoma bleeding puncture site minor
6.2%
23/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
2.5%
4/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Vascular disorders
Angina, Stable
6.2%
23/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
6.9%
11/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Vascular disorders
Angina, Unstable
3.2%
12/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
1.2%
2/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Cardiac disorders
Arrythmia - other
3.5%
13/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
6.2%
10/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Vascular disorders
Hypertension
5.6%
21/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
5.6%
9/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Vascular disorders
Hypotension
3.5%
13/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
1.9%
3/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Vascular disorders
Other - Cardiovascular
11.6%
43/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
14.4%
23/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Endocrine disorders
Diabetes Melitus Type II
3.2%
12/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
4.4%
7/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Gastrointestinal disorders
Nausea
3.5%
13/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
1.2%
2/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Gastrointestinal disorders
Other- gastrointestinal
10.5%
39/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
6.9%
11/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Infections and infestations
Infection, local
5.4%
20/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
7.5%
12/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Infections and infestations
Other infectious
3.2%
12/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
2.5%
4/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Nervous system disorders
Dizziness/ vertigo
5.1%
19/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
5.6%
9/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Nervous system disorders
Other neurological/ nervous system
10.2%
38/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
8.1%
13/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Respiratory, thoracic and mediastinal disorders
Bronchitis
5.9%
22/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
3.1%
5/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Respiratory, thoracic and mediastinal disorders
Cough
4.6%
17/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
3.1%
5/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Respiratory, thoracic and mediastinal disorders
Dyspnea
6.5%
24/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
4.4%
7/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Respiratory, thoracic and mediastinal disorders
Other respiratory
9.7%
36/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
11.2%
18/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Respiratory, thoracic and mediastinal disorders
Pneumonia
4.3%
16/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
2.5%
4/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Musculoskeletal and connective tissue disorders
Arthralgia
4.3%
16/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
2.5%
4/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Musculoskeletal and connective tissue disorders
Arthritis
3.8%
14/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
5.0%
8/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Musculoskeletal and connective tissue disorders
Back pain
12.1%
45/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
5.0%
8/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Musculoskeletal and connective tissue disorders
Fracture (bone)
4.6%
17/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
4.4%
7/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Musculoskeletal and connective tissue disorders
Claudication
6.5%
24/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
10.6%
17/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Musculoskeletal and connective tissue disorders
Other skeletal, spine and muscular system
31.5%
117/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
21.9%
35/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
General disorders
Dissection
3.0%
11/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
3.8%
6/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Vascular disorders
Restenosis
3.5%
13/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
1.9%
3/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Vascular disorders
Restenosis in target vessel
3.8%
14/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
1.9%
3/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Renal and urinary disorders
Renal failure/ insufficiency
5.9%
22/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
3.1%
5/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Renal and urinary disorders
Urinary infection
7.0%
26/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
5.6%
9/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Renal and urinary disorders
Other, genito-urinary system
6.5%
24/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
8.1%
13/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Skin and subcutaneous tissue disorders
Rash
3.2%
12/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
3.1%
5/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
General disorders
Other
42.2%
157/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
41.9%
67/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Vascular disorders
Stenosis
4.0%
15/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
3.1%
5/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
Vascular disorders
Other vessel specific
3.8%
14/372 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.
1.9%
3/160 • 60 months
All adverse events occurring in this study will be classified in accordance with the adverse event signs or symptoms. Both Non-Serious Adverse Events (AE) and Serious Adverse Events (SAE) are reported with a threshold of 3%.

Additional Information

Anna Lovas

Becton Dickinson

Phone: 7634452382

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place

Restriction type: GT60